hIL-6 NOG

hIL-6 NOG Mouse Model
  • Live
  • Mouse
  • Male & Female Available
  • Albino
  • Available for direct purchase by CRO
Model No.NomenclatureGenotype
13686-FNOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)1-1Jic/JicTacsp/sp;ko/ko;tg/wt
13686-MNOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)1-1Jic/JicTacsp/sp;ko/y;tg/wt
View:
Select One

Overview

Nomenclature: NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)1-1Jic/JicTac

  • Super immunodeficient NOG mouse expressing human IL-6 cytokine
  • Enhanced expansion of human monocytes following human HSC engraftment
  • May be useful for study of tumor-infiltrating macrophages
  • May be suitable host for hIL-6 dependent multiple myeloma (MM) patient derived xenograft (PDX) and tumor samples.
  • Applications in research involving cancer, immunology, regenerative medicine and human immune system engraftment
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:

“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH

Availability

Available now*
*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age.

Origin

The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The linearized hIL-6 transgene was injected into zygotes from NOD/Shi-IL2rg females x NOD/Shi-IL2rg males.  The transgenic hIL-6 NOD/Shi-IL2rg mouse was crossed on to the NOG background to introduce the Prkdc scid mutation.  The mice were backcrossed onto the NOG background three times.  Taconic received stock in 2014, and the line was derived through embryo transfer.

Genetics

Species:Mouse
Strain Type:Congenic
Allele Type:Constitutive Knockout;Spontaneous Mutant;Random Transgenic;Genetically Humanized
Coat Color:Albino
Genetic Background:NOD

Guides & Publications

Initial Publication: Hanazawa A, Ito R, Katano I, Kawai K, Goto M, Suemizu H, Kawakami Y, Ito M, Takahashi T. (2018) Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. Front Immunol 9:152.

Applications & Therapeutic Areas

  • Immunology
  • Inflammation
  • Oncology & Immuno-Oncology
  • Cell and Tissue Humanized

Transit, Housing & Welfare

Need more info? Click the live chat button or Contact Us

Packing Practices

Taconic standard practice is to recombine animals of different home cages and/or ages from a single model and sex during packing, except in specific cases where Taconic's animal welfare policy prohibits recombination due to aggression or other concerns.  When an order is fulfilled with animals from more than one week of birth, this standard practice results in animals from a range of birth weeks packed together in a single TTC. When an order is fulfilled with animals from genotyped models, this standard practice results in animals from different home cages packed together in a single TTC.

Customers who wish to keep animals from different weeks of birth separated should place orders with the special instruction "Divide and label by age."  Note that this special request can result in increased costs for additional Taconic Transit Cages, dividers and/or freight charges.

Data

Humanized hIL-6 NOG Mice Supports Human Monocytes/Macrophages & Immunosuppressive Human Tumor Microenvironment

Development of human monocytes/macrophages in hIL-6 NOG engrafted with human CD34+ stem cells

Figure 1: (a) The frequency of CD33+CD14+ monocytes/macrophages in hCD45+ leukocytes, obtained by flow cytometry. (b) The absolute number of CD33+CD14+ monocytes/macrophages, calculated by multiplying the number of total MNCs by the frequencies of each human subpopulation determined by FACS. (c) The distributions of human macrophages in HSC-engrafted NOG and hIL-6 NOG mice, assessed in paraffin-embedded lung, liver, spleen, and BM. Adapted from Hanazawa, et al. 2018 under Creative Commons Attribution License.

 

Development of human tumor-associated macrophages (TAMs) in tumor-engrafted humanized hIL-6 NOG mice

Development of human tumor-associated macrophages (TAMs) in tumor-engrafted humanized hIL-6 NOG mice
Figure 2: (a) Schema of generation of tumor-bearing humanized mice. (b) Immunohistochemistry of human macrophages in tumor and spleen at 36-51 days after tumor transplantation. (c) Enumeration of CD68+ or CD163+ macrophages. (d) Expression of IL-4Rα in human macrophages. FACS plots of IL-4Rα in hCD45+CD14+CD68+ macrophages in tumor, spleen, and PB of HSC4-engrafted HSC-NOG-hIL-6 Tg (upper panels) and histogram of hIL-4Rα expression in hCD68+ macrophages in various tissues (bottom panel). Adapted from Hanazawa, et al. 2018 under Creative Commons Attribution License.

hIL-6 NOG

Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions.

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:

  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Pricing - USD

Opportunist Free (OF) Health Standard

13686 Female

13686-F Genotype sp/sp;ko/ko;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10$501.00

13686 Male

13686-M Genotype sp/sp;ko/y;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10$501.00

Pricing - EUR

Opportunist Free (OF) Health Standard

13686 Female

13686-F Genotype sp/sp;ko/ko;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10€441,00

13686 Male

13686-M Genotype sp/sp;ko/y;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10€441,00

Pricing - USD Nonprofit

Opportunist Free (OF) Health Standard

13686 Female

13686-F Genotype sp/sp;ko/ko;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10$321.00

13686 Male

13686-M Genotype sp/sp;ko/y;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10$321.00

Pricing - EUR Nonprofit

Opportunist Free (OF) Health Standard

13686 Female

13686-F Genotype sp/sp;ko/ko;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10€257,00

13686 Male

13686-M Genotype sp/sp;ko/y;tg/wt

Age in WeeksQuantity 1 - 999
3 to 10€257,00

Select my Health Standard

Need help choosing the right Taconic Biosciences health standard for your research?

Use the Health Standard Selector to enter your exclusion list. The tool will tell you which health standards meet your requirements.

Get custom pricing guide

2024 Pricing Guide Now Available

Get your Taconic Biosciences 2024 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.

Looking for More Information

Schedule A Scientific Consultation

We provide you with coupled capabilities and service offerings, enabling your researchers to work with a single provider to meet their study needs while enjoying a more streamlined integrated process at any stage of a project.

Speak with a Colony Management Specialist and Field Application Scientist that can help you develop and deploy the tailored solution you need.

Want to Get in Touch?

Chat with us or reach out to our global team

phone

Webinar On-Demand

ON-DEMAND WEBINAR | Humanized Mice in Preclinical Immuno-Oncology - Part I

Webinar On-Demand

ON-DEMAND PRESENTATION | Humanized Immune System (HIS) Mice: Breakthrough Models for Immuno-Oncology Drug Discovery

Webinar On-Demand

ON-DEMAND WEBINAR | Development and Characteristics of hIL-6 NOG Mouse

White Paper

Humanized Mouse Models for Drug Discovery: The NOG Portfolio | WHITE PAPER
wp

2024 Pricing Guide Now Available

Get your Taconic Biosciences 2024 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.

Smart Select Program

Trial an Animal Model for Quality & Compatibility Assurance

As longtime facilitators of animal-based research, we understand the importance of aligning your project goals and procurement priorities to support advancements in your research. 

  • Evaluate a specific model strain, before making any financial investment
  • Request up to 20 animals from one of the strains listed below, to test for quality, consistency, and suitability for your experimental purpose
  • Enjoy free ground shipping, where applicable (see table for more details)*